Developer of an innovative drug design and development engine focused on the use of structure-based design to improve the drug discovery process. The company uses its structure-based design approach on targets that have been validated to progress compounds through lead optimisation and clinical development. The company's focus is on two therapeutic areas, anti-bacterials and anti-cancers, which are complementary in managing risk within a research and development portfolio. The drug design and development engine utilises in silico screening together with detailed ligand and fragment based approaches to generate hit compounds. Assay, structural and computational approaches are used to progress high quality, validated lead candidates to pre-clinical development. This "structure to development candidate" platform enhances the drug-like features of leads, improving their quality and potential to succeed.